TriangleHEALTH PROFESSIONAL · SOURCE READING
Taxanes
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Paclitaxel has shown activity in both AIDS-associated and classic KS in small case series.[9-12]
Evidence (taxanes):
A small trial included 73 patients with AIDS-associated KS (32% had an undetectable HIV viral load). Patients were randomly assigned to receive either PLD or paclitaxel.[9]
Source links and citations
A small trial included 73 patients with AIDS-associated KS (32% had an undetectable HIV viral load). Patients were randomly assigned to receive either PLD or paclitaxel.[9]
Response rates were 46% for patients who received PLD and 56% for patients who received paclitaxel. The median progression-free survival (PFS) was 12 months for patients who received PLD and 18 months for patients who received paclitaxel. The 2-year overall survival rates were 78% for patients who received PLD and 79% for patients who received paclitaxel.[9][Level of evidence B3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice